4D Molecular Therapeutics Income Statement (2019-2026) | FDMT

Income Statement Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
1.37M0.09M1.22M0.16M0.50M1.25M0.30M0.24M20.20M-0.02M0.03M0.01M0.00M0.00M0.01M0.01M0.09M85.09M3.05M3.78M
Operating items
Research & Development (Quarter)
15.84M17.53M19.38M20.42M18.94M21.50M22.41M23.58M25.07M26.03M27.87M31.86M38.48M43.09M40.70M47.95M49.44M57.61M64.98M68.28M
Selling, General & Administrative (Quarter)
8.19M7.33M8.23M8.17M8.05M8.47M7.99M8.79M9.11M10.61M10.29M10.60M12.65M13.03M12.94M11.52M11.84M12.77M11.69M12.52M
Operating Expenses (Quarter)
24.03M24.86M27.61M28.59M27.00M29.97M30.40M32.38M34.18M36.63M38.16M42.46M51.13M56.12M53.63M59.47M61.27M70.38M76.67M80.81M
Operating Income (Quarter)
-22.66M-24.76M-26.39M-28.43M-26.50M-28.72M-30.11M-32.14M-13.97M-36.65M-38.14M-42.46M-51.13M-56.12M-53.62M-59.46M-61.19M14.71M-73.62M-77.03M
EBIT (Quarter)
-22.66M-24.76M-26.39M-28.43M-26.50M-28.72M-30.11M-32.14M-13.97M-36.65M-38.14M-42.46M-51.13M-56.12M-53.62M-59.46M-61.19M14.71M-73.62M-77.03M
Non-operating items
Interest & Investment Income (Quarter)
0.43M-0.31M-1.00M-0.41M0.80M1.34M0.93M0.61M3.88M4.38M-0.12M-0.18M7.29M6.47M5.58M0.01M4.33M4.70M4.86M4.25M
Other Non Operating Income (Quarter)
-0.01M-0.01M-0.05M0.01M0.00M-0.02M0.01M-0.16M-0.01M-0.01M-0.04M-0.00M-0.02M0.07M-0.06M-0.02M-0.02M-0.00M-0.17M
Non Operating Income (Quarter)
0.42M-0.32M0.05M0.34M0.80M1.34M1.42M2.52M3.72M4.37M5.74M7.50M7.29M6.45M5.65M4.80M4.31M4.68M4.86M4.09M
Net income details
EBT (Quarter)
-47.53M-26.28M-33.13M-34.23M-47.32M-30.28M-49.29M-51.28M-29.08M-33.07M-39.06M-45.45M-77.95M-50.55M-49.44M-89.89M-85.88M18.02M-94.91M-97.48M
Profit After Tax (Quarter)
-22.24M-25.08M-26.34M-28.09M-25.69M-27.38M-28.68M-29.62M-10.26M-32.28M-32.40M-34.95M-43.84M-49.67M-47.97M-54.66M-56.88M19.40M-68.76M-72.94M
Income from Continuing Operations (Quarter)
-47.53M-26.28M-33.13M-34.23M-47.32M-30.28M-49.29M-51.28M-29.08M-33.07M-39.06M-45.45M-77.95M-50.55M-49.44M-89.89M-85.88M18.02M-94.91M-97.48M
Consolidated Net Income (Quarter)
-47.53M-26.28M-33.13M-34.23M-47.32M-30.28M-49.29M-51.28M-29.08M-33.07M-39.06M-45.45M-77.95M-50.55M-49.44M-89.89M-85.88M18.02M-94.91M-97.48M
Income towards Parent Company (Quarter)
-47.53M-26.28M-33.13M-34.23M-47.32M-30.28M-49.29M-51.28M-29.08M-33.07M-39.06M-45.45M-77.95M-50.55M-49.44M-89.89M-85.88M18.02M-94.91M-97.48M
Net Income towards Common Stockholders (Quarter)
-22.24M-25.08M-26.34M-28.09M-25.69M-27.38M-28.68M-29.62M-10.26M-32.28M-32.40M-34.95M-43.84M-49.67M-47.97M-54.66M-56.88M19.40M-68.76M-72.94M
Additional items
EPS (Basic) (Quarter)
-0.82-0.90-0.82-0.87-0.79-0.85-0.88-0.77-0.24-0.83-0.66-0.63-0.79-0.92-0.86-0.98-1.010.33-1.01-1.04
EPS (Diluted) (Quarter)
-0.82-0.90-0.82-0.87-0.79-0.85-0.88-0.77-0.24-0.83-0.66-0.63-0.79-0.92-0.86-0.98-1.010.33-1.01-1.04
Shares Outstanding (Quarter)
27.02M27.73M32.23M32.32M32.39M32.35M32.72M38.34M42.26M39.13M49.27M55.28M55.55M53.94M55.74M55.93M56.13M57.93M68.06M70.27M
Shares Outstanding (Diluted) (Quarter)
27.02M27.73M32.23M32.32M32.39M32.35M32.72M38.34M42.26M39.13M49.27M55.28M55.55M53.94M55.74M55.93M56.13M57.93M68.06M70.27M
Shares Outstanding (Entity) (Quarter)
27.17M32.22M32.26M32.38M32.39M32.63M33.24M42.02M42.75M43.08M51.16M51.91M52.00M45.79M46.32M46.70M46.77M57.61M68.06M70.27M
EBITDA (Quarter)
-22.66M-24.76M-26.39M-28.43M-26.50M-28.72M-30.11M-32.14M-13.97M-36.65M-38.14M-42.46M-51.13M-56.12M-53.62M-59.46M-61.19M14.71M-73.62M-77.03M
Interest Expenses (Quarter)
25.31M1.20M5.74M5.39M21.62M2.90M20.11M19.75M18.99M0.80M0.80M2.81M34.11M0.90M1.40M30.44M29.02M1.40M26.16M24.71M